EQS-News: Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
|
EQS-News: Eckert & Ziegler SE
/ Key word(s): Incoming Orders/Agreement
Berlin, DE & Hamilton, ON, CA, 20 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand®) to support AtomVie’s CDMO activities for radiopharmaceutical manufacturing.
20.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Eckert & Ziegler SE |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-0 |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, TecDax, |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2103808 |
| End of News | EQS News Service |
|
|
2103808 20.03.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 178,49 | 176,14 | 180,44 | 222,26 | 246,09 | 295,85 | 320,00 | |
| EBITDA1,2 | 43,13 | 44,64 | 57,04 | 55,52 | 58,83 | 78,80 | 90,00 | |
| EBITDA-Margin3 | 24,16 | 25,34 | 31,61 | 24,98 | 23,91 | 26,64 | 28,13 | |
| EBIT1,4 | 32,06 | 33,69 | 47,45 | 44,54 | 45,45 | 59,95 | 75,00 | |
| EBIT-Margin5 | 17,96 | 19,13 | 26,30 | 20,04 | 18,47 | 20,26 | 23,44 | |
| Net Profit (Loss)1 | 22,48 | 23,11 | 34,66 | 29,75 | 26,77 | 34,11 | 50,00 | |
| Net-Margin6 | 12,60 | 13,12 | 19,21 | 13,39 | 10,88 | 11,53 | 15,63 | |
| Cashflow1,7 | 40,43 | 36,79 | 33,86 | 34,30 | 47,40 | 66,57 | 72,00 | |
| Earnings per share8 | 1,07 | 1,11 | 1,66 | 1,41 | 1,26 | 1,59 | 2,35 | |
| Dividend per share8 | 0,42 | 0,45 | 0,50 | 0,50 | 0,05 | 0,50 | 0,55 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Forvis Mazars
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Eckert & Ziegler | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 565970 | DE0005659700 | SE | 1.244,91 Mio € | 25.05.1999 | Kaufen | 9F4MJGG3+WR |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 23,33 | 27,91 | 0,84 | 47,50 | 5,84 | 18,70 | 4,21 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,50 | 0,05 | 0,50 | 0,85% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 18.06.2025 | 13.05.2025 | 08.08.2025 | 13.11.2025 | 27.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +5,41% | +28,36% | +32,13% | +83,58% | +922,61% |
